EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.

KRO posts a wider-than-expected Q3 loss as lower TiO2 prices and weak demand hit sales, with volumes under pressure.

KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

PBF posts narrower Q3 loss as cost cuts lift results, though revenues and throughput volumes fall year over year.

UGI posts a narrower Q4 loss and higher full-year earnings despite revenue softness and mixed performance across segments.

CSIQ's Q3 loss is narrower than expected as revenues beat estimates, buoyed by stronger margins from battery storage.

Rigetti's Q3 loss is narrower than estimates, but revenues decline as government contract delays hit sales and lower the gross margin.

Rigetti's Q3 loss is narrower than estimates, but revenues decline as government contract delays hit sales and lower the gross margin.